Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK; ADDUCE consortium.

CNS Drugs. 2017 Mar;31(3):199-215. doi: 10.1007/s40263-017-0410-7. Review.

2.

Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor.

Kotańska M, Śniecikowska J, Jastrzębska-Więsek M, Kołaczkowski M, Pytka K.

Front Neurosci. 2017 Feb 8;11:50. doi: 10.3389/fnins.2017.00050. eCollection 2017.

3.
4.

Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.

Lyauk YK, Stage C, Bergmann TK, Ferrero-Milliani L, Bjerre D, Thomsen R, Dalhoff KP, Rasmussen HB, Jürgens G.

Clin Transl Sci. 2016 Dec;9(6):337-345. doi: 10.1111/cts.12423. Epub 2016 Oct 18.

5.

Clevidipine resistance in a patient taking aripiprazole and methylphenidate.

Jacklen MA, Campagna JA, Tobias JD.

J Exp Pharmacol. 2014 Oct 17;6:11-4. doi: 10.2147/JEP.S71914. eCollection 2014.

6.

Cardiac Arrest following a Myocardial Infarction in a Child Treated with Methylphenidate.

Munk K, Gormsen L, Kim WY, Andersen NH.

Case Rep Pediatr. 2015;2015:905097. doi: 10.1155/2015/905097. Epub 2015 Jun 28.

7.

Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder.

Lamberti M, Italiano D, Guerriero L, D'Amico G, Siracusano R, Ingrassia M, Germanò E, Calabrò MP, Spina E, Gagliano A.

Neuropsychiatr Dis Treat. 2015 May 8;11:1169-74. doi: 10.2147/NDT.S79866. eCollection 2015.

8.

Exercise outcomes in prevalent users of stimulant medications.

Westover AN, Nakonezny PA, Barlow CE, Vongpatanasin W, Adinoff B, Brown ES, Mortensen EM, Halm EA, DeFina LF.

J Psychiatr Res. 2015 May;64:32-9. doi: 10.1016/j.jpsychires.2015.03.011. Epub 2015 Mar 21.

9.

Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell.

De Luca MA, Valentini V, Bimpisidis Z, Cacciapaglia F, Caboni P, Di Chiara G.

Front Psychiatry. 2014 Oct 17;5:140. doi: 10.3389/fpsyt.2014.00140. eCollection 2014.

10.

Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity.

Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, Tomasi D.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3149-56. doi: 10.1073/pnas.1411228111. Epub 2014 Jul 14.

11.

Methylphenidate remediates error-preceding activation of the default mode brain regions in cocaine-addicted individuals.

Matuskey D, Luo X, Zhang S, Morgan PT, Abdelghany O, Malison RT, Li CS.

Psychiatry Res. 2013 Nov 30;214(2):116-21. doi: 10.1016/j.pscychresns.2013.06.009. Epub 2013 Aug 23.

12.

Neural correlates of motor vigour and motor urgency during exercise.

Rauch HG, Schönbächler G, Noakes TD.

Sports Med. 2013 Apr;43(4):227-41. doi: 10.1007/s40279-013-0025-1. Review.

13.

Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.

Westover AN, Nakonezny PA, Winhusen T, Adinoff B, Vongpatanasin W.

J Clin Hypertens (Greenwich). 2013 Feb;15(2):124-32. doi: 10.1111/jch.12039. Epub 2012 Dec 14.

14.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

15.

Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.

Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BS, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R.

Am J Psychiatry. 2012 Feb;169(2):167-77. doi: 10.1176/appi.ajp.2011.10111705.

16.

Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients.

Li CS, Morgan PT, Matuskey D, Abdelghany O, Luo X, Chang JL, Rounsaville BJ, Ding YS, Malison RT.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14455-9. doi: 10.1073/pnas.1002467107. Epub 2010 Jul 26.

17.

Catecholamines 101.

Goldstein DS.

Clin Auton Res. 2010 Dec;20(6):331-52. doi: 10.1007/s10286-010-0065-7. Epub 2010 Jul 11.

18.

Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate.

Engert V, Pruessner JC.

Curr Neuropharmacol. 2008 Dec;6(4):322-8. doi: 10.2174/157015908787386069.

19.

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS.

Am J Hum Genet. 2008 Jun;82(6):1241-8. doi: 10.1016/j.ajhg.2008.04.015. Epub 2008 May 15.

20.

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Vitiello B.

Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):459-74, xi. doi: 10.1016/j.chc.2007.11.010. Review.

Supplemental Content

Support Center